Cancer and TNF antibodies boost Biologics Sales in 2007
Epoetin alfa brands still are number one drugs with 2007 sales of US$ 5.76bln, but closely followed by (anti-TNF) etanercept with 2007 sales of US$ 5.45 bln and apositive double digit growth rate in contrast to epoetin. The Lucentis antibody fortreatment of age-related macular degeneration (AMD) has become the newestblockbuster biologic with sales higher than US$ 1 bln in 2007.
New enzyme replacementproducts explain the 2nd strongest growth by 34.1% of this class of biologic therapies.The continued double digit growth of novel insulin analogs made the class of recombinantinsulins pass the threshold of US$ 10 bln sales in 2007. These results and more were found in an an elaboration prepared by La Merie Business Intelligence and published in a complimentary report on March 27, 2008.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous